A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Moderate to Severe Plaque Psoriasis
Спонсор: Janssen Cilag International
Налично на:
БГ
Обобщение
Trial status: Authorised
IGA score of 0 or 1 and a ≥2 grade improvement from baseline at Week 16., PASI 90 at Week 16.
Кой може да участва
Age group: 18-64 years, 65+ years, 0-17 years
Gender: Female, Male
Target enrollment: 434 participants
Интервенции
STELARA 90 mg solution for injection in pre-filled syringe
Drug
Solution for injection without Ustekinumab 45
Drug
JNJ-77242113
Drug
Film-Coated Tablet without JNJ-77242113
Drug
Solution for injection in pre-filled syringe without Ustekinumab 90
БГ
EN